CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population

Pharmacogenomics

Volumn 10, Issue 2, 2009, Pages 261-266

  Borgiani, Paola ^a   Ciccacci, Cinzia ^a   Forte, Vittorio ^b   Siríanni, Elisabetta ^a   Novelli, Lucía ^a   Bramanti, Placido ^c   Novelli, Giuseppe ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

CYP4F2; Drug dosing; Genomic biomarkers; Mean weekly warfarin dose; MWWD; Pharmacogenetics; Pharmacogenomics; SNP; Warfarin

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; CYTOSINE; GENE PRODUCT; PROTEIN VKORC1; TYROSINE; UNCLASSIFIED DRUG; WARFARIN; ANTICOAGULANT AGENT; CYP4F2 PROTEIN, HUMAN; DNA; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE;

AGED; AORTA VALVE PROSTHESIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DNA EXTRACTION; DOSE RESPONSE; DRUG DOSE COMPARISON; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HEREDITY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE PROSTHESIS; COHORT ANALYSIS; GENETICS; HEART VALVE REPLACEMENT; ISOLATION AND PURIFICATION; VEIN THROMBOSIS;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC VARIATION; GENOTYPE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; ITALY; MALE; MIXED FUNCTION OXYGENASES; ROME; VENOUS THROMBOSIS; WARFARIN;

EID: 65549085682     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.10.2.261     Document Type: Article

References (21)

1. Hirsh J, Dalen J, Anderson DR et al.: Oral. anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119(Suppl. 1) S8-S21 (2001).
2. Sconce EA, Khan TI, Wynne HA et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005).
3. Sconce EA, Kamali F: Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen. Eur. J. Haematol. 77(6), 457-462 (2006).
4. Aquilante CL, Langaee TY, Lopez LM et al.: Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79(4), 291-302 (2006).
5. Yin T, Miyata T: Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb. Res. 120(1), 1-10 (2007).
6. van Aken J, Schmedders M, Feuerstein G, Kollek R: Prospects and limits of pharmacogenetics: the thiopurine methyl transferase (TPMT) experience. Am. J. Pharmacogenomics 3(3), 149-155 (2003).
7. Rieder MJ, Reiner AP, Gage BF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005).
8. Veenstra DL, You JH, Rieder MJ et al.: Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics 15, 687-691 (2005).
9. Wadelius M, Chen LY, Downes K et al.: Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5, 262-270 (2005).
10. D'Andrea G, D'Ambrosio RL, Di Perna P et al.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105, 645-649 (2005).
11. Vecsler M, Loebstein R, Almog S et al.: Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin. Thromb. Haemost. 95, 205-111 (2006).
12. Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, Novelli G: Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics 8(11), 1545-1550 (2007).
13. Wu AH, Wang P, Smith A et al.: Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 9(2), 169-178 (2008).
14. Schwarz UI, Ritchie MD, Bradford Y et al.: Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358(10), 999-1008 (2008).
15. Flockhart DA, O'Kane D, Williams MS et al.: Testing of CYP2C9, VKORC1 alleles for warfarin use pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet. Med. 10(2), 139-150 (2008).
16. Carlquist JF, Horne BD, Muhlestein JB et al.: Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J. Thromb. Thrombolysis 22(3), 191-197 (2006).
17. Geisen C, Watzka M, Sittinger K et al.: VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb. Haemost. 94(4), 773-779 (2005).
18. Yuan HY, Chen JJ, Lee MT et al.: A novel functional VKORC1 promoter polymorphism is associated with inter-individual and interethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14, 1745-1751 (2005).
19. Caldwell MD, Awad T, Johnson JA et al.: CYP4F2 genetic variant alters required warfarin dose. Blood 111(8), 4106-4112 (2008).
20. Cooper GM, Johnson JA, Langaee TY et al.: A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112(4), 1022-1027 (2008).
21. Novelli G, Ciccacci C, Borgiani P, Papaluca-Amati M, Abadie E: Genetic tests and genomic biomarkers: regulation, qualification and validation. Clinical Cases in Mineral and Bone Metabolism 5(2), 149-154 (2008).